Jaguar Health Inc  

(Public, NASDAQ:JAGX)   Watch this stock  
Find more results for JAGX
0.131
+0.001 (0.77%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.12 - 0.14
52 week 0.10 - 1.52
Open 0.13
Vol / Avg. 2.79M/3.55M
Mkt cap 13.85M
P/E     -
Div/yield     -
EPS -1.04
Shares 104.94M
Beta     -
Inst. own 15%
Nov 14, 2017
Q3 2017 Jaguar Health Inc Earnings Call
Nov 14, 2017
Q3 2017 Jaguar Health Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -201.41% -10411.09%
Operating margin -262.15% -9676.36%
EBITD margin - -9566.49%
Return on average assets -170.15% -184.54%
Return on average equity - -1515.11%
Employees 17 -
CDP Score - -

Address

201 Mission St Ste 2375
SAN FRANCISCO, CA 94105-1839
United States - Map
+1-415-8965081 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Officers and directors

James J. Bochnowski Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Lisa A. Conte President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Karen S. Wright Chief Financial Officer
Bio & Compensation  - Reuters
Steven R. King Ph.D. Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary
Age: 59
Bio & Compensation  - Reuters
Roger Waltzman Executive Officer
Bio & Compensation  - Reuters
Ari Azhir PhD Director
Age: 69
Bio & Compensation  - Reuters
Folkert W. Kamphuis Director
Age: 56
Bio & Compensation  - Reuters
John J. Micek III J.D. Director
Age: 63
Bio & Compensation  - Reuters
Jiahao Qiu Director
Age: 30
Bio & Compensation  - Reuters
Zhi Yang Ph.D. Director
Age: 58
Bio & Compensation  - Reuters